[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-ischemic-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,230,0,25,[9,48,77,99,123,147,170,196,218,245,270,298,319,346,372,393,416,441,465,487,505,526,551,576,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100644695","endovascular-therapy-for-acute-basilar-artery-occlusion-with-large-ischemic-core-100644695",false,"NCT07672795","Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core","Efficacy and Safety of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical symptoms or imaging findings suggestive of acute posterior circulation ischemic stroke.\n* Basilar artery occlusion confirmed by CTA, MRA, or DSA.\n* Posterior circulation ASPECTS \\\u003C7 on CT, CTA source images, or MRI-DWI.\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Written informed consent obtained from the patient or legally authorized representative.\n* Baseline NIHSS score ≥6 before randomization.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score ≥3.\n* Pregnancy or lactation.\n* Known allergy to contrast agents or nickel-titanium alloy.\n* Current participation in another clinical trial.\n* Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy.\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, or current oral anticoagulant use with INR \\>1.7.\n* Blood glucose \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL, platelet count \\\u003C50 × 10\\^9\u002FL, or hematocrit \\\u003C25%.\n* Life expectancy less than 1 year.\n* Inability to complete 90-day follow-up.\n* Definite history of cerebral vasculitis.\n* Pre-existing neurological or psychiatric disorder that may interfere with neurological or functional assessment.\n* Intracranial hemorrhage on CT or MRI, except for cerebral microbleeds \\\u003C5 mm on MRI.\n* Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that precludes endovascular treatment.\n* Intracranial tumor, except for small meningioma.","ALL","18 Years",{"count":20,"type":21},256,"ESTIMATED","INTERVENTIONAL",[24],"NA","Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.\n\nThis prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \\\u003C7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.",[27,28,29],"Acute Ischemic Stroke","Basilar Artery Occlusion","Large Ischemic Core",[31,32,33,34,35],"Basilar artery occlusion","Endovascular therapy","Mechanical thrombectomy","Posterior circulation stroke","Large ischemic core","NOT_YET_RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":21},"2026-08-01",{"date":44,"type":21},"2029-12-31",{"name":46,"class":47},"The First Affiliated Hospital of University of Science and Technology of China","OTHER",{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100518357","the-pivotal-study-of-rapidpulsetm-aspiration-system-100518357","NCT06029491","The Pivotal Study of RapidPulseTM Aspiration System","The Pivotal Study of RapidPulseTM Aspiration System as Frontline Approach for Patient With Acute Ischemic Stroke Due to Large Vessel Occlusions","PIVOTAL","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6\n* Able to be treated within 8 hours of symptom onset or last known normal (LKN)\n* Able to be treated within 120 minutes from the time of the qualifying baseline CT\u002FMR image\n* Pre-morbid Modified Rankin Scale (mRS) score 0-1\n* Angiographic confirmation of large vessel occlusion (LVO) in the anterior (intracranial ICA or MCA M1 or M2 segments) or posterior circulation (vertebral or basilar arteries) as confirmed by digital subtraction angiography (DSA) irrespective of IV thrombolysis administration\n* Candidate to receive treatment with ADAPT technique (Direct Aspiration First-Pass Technique)\n\nExclusion Criteria:\n\n* Intracranial Hemorrhage (ICH)\n* Alberta Stroke Program Early CT Score (ASPECTS) \\\u003C6\n* Intracranial Atherosclerotic Disease (ICAD)\n* Multiple or tandem occlusions\n* Life expectancy less than 6 months","80 Years",{"count":58,"type":21},170,[24],"The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.",[27],[63,64,65,66],"Stroke","Large Vessel Occlusion","Mechanical Thrombectomy","Neurovascular Intervention","RECRUITING",{"date":39,"type":40},{"date":70,"type":40},"2025-03-27",{"date":72,"type":21},"2027-04",{"name":74,"class":75},"RapidPulse, Inc","INDUSTRY",30,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100635254","phase-2-repeated-intravenous-thrombolysis-for-ischemic-stroke-with-medium-to-large-vessel-occlusion-presenting-within-45-hours-of-onset-with-prourokinase-100635254","NCT07550296","Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase","Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase (RITIS-PUK): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","Inclusion Criteria:\n\n* Age ≥ 18 year;\n* Acute ischemic stroke presumably caused by large or medium vessel occlusion within 4.5 hours of onset, having received intravenous thrombolysis of prourokinase, and with no planned thrombectomy;\n* Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4;\n* Baseline pc-ASPECTS\u002FASPECTS ≥ 6, and for posterior circulation infarction, a Pontine-Midbrain Index ≤ 2 (assessed by CT or DWI);\n* No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis;\n* Follow-up imaging (CTA or MRA) at 1 hour after the first thrombolysis rules out intracranial hemorrhage and confirms the presence of large or medium vessel occlusion (internal carotid artery, M1-M3 segments of the middle cerebral artery, A1-A3 segments of the anterior cerebral artery, P1-P3 segments of the posterior cerebral artery, basilar artery or V4 segment of the vertebral artery, PICA, AICA, or SCA);\n* The second intravenous thrombolysis can be administered within 6 hours of onset;\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Planed for endovascular treatment;\n* Significant white matter hyperintensities (Fazekas score 3);\n* Any coagulation abnormality before the first thrombolysis, including INR \\> 1.5;\n* Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis.；\n* Pregnancy；\n* Allergy to the investigational drug(s)；\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.",{"count":85,"type":21},122,[87],"PHASE2","Ischemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment. Current reperfusion strategies include intravenous thrombolysis (IVT) and endovascular therapy (EVT). Although alteplase is the first-line thrombolytic agent, its recanalization rate for large vessel occlusion (LVO) is only 10-20%, and for medium vessel occlusion (MeVO), approximately 50% of patients fail to achieve recanalization, leading to poor outcomes. Prourokinase has recently been shown to be non-inferior to alteplase with a better safety profile, and studies suggest that repeated thrombolysis may improve recanalization rates in patients without early clinical improvement after standard IVT. Therefore, this study aims to evaluate the efficacy and safety of an additional intravenous infusion of prourokinase in AIS patients with confirmed medium or large vessel occlusion who show no significant clinical improvement at 1 hour after standard IVT (within 4.5 hours of symptom onset). Patients without early neurological improvement (e.g., \\\u003C2-point reduction in NIHSS) and persistent vessel occlusion on imaging will receive a second dose of prourokinase. The primary outcomes include 24-hour recanalization rate (by CTA\u002FMRA), 90-day functional outcome (modified Rankin Scale), and safety endpoints (symptomatic intracranial hemorrhage, mortality). The hypothesis is that additional prourokinase following standard IVT in non-improving patients with medium or large vessel occlusion will significantly increase recanalization rates and improve clinical outcomes without an unacceptable increase in symptomatic intracranial hemorrhage.",[27],"2026-06-29",{"date":37,"type":40},{"date":93,"type":40},"2026-05-06",{"date":95,"type":21},"2027-12-30",{"name":97,"class":47},"General Hospital of Shenyang Military Region",1,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100635691","superstar-aspiration-vs-stent-retriever-in-anterior-circulation-lvo-100635691","NCT07555977","SUPERSTAR: Aspiration vs. Stent Retriever in Anterior Circulation LVO","Super Large Bore Catheter Aspiration Versus Stent Retriever Thrombectomy as First Line Technique for Anterior Circulation Large Vessel Occlusion in Acute Ischemic Stroke","SUPERSTAR","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Clinically diagnosed with acute ischemic stroke, and pre-procedure imaging confirms that the culprit vessel is occlusion of the intracranial segment of the internal carotid artery and\u002For the middle cerebral artery M1 segment;\n3. Pre-stroke modified Rankin Scale (mRS) score of 0-1;\n4. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 6;\n5. Alberta Stroke Program Early CT Score (ASPECTS) ≥ 3;\n6. Time from symptom onset to initiation of endovascular treatment (arterial puncture) \\\u003C 24 hours; symptom onset time is defined as the \"last known well\" time;\n7. Intravenous thrombolysis and\u002For mechanical thrombectomy are performed according to local guidelines, and intravenous thrombolysis does not delay mechanical thrombectomy;\n8. Written informed consent is obtained from the patient or a family member.\n\nExclusion Criteria:\n\n1. Imaging shows acute or subacute intracranial hemorrhage (excluding microbleeds);\n2. Imaging indicates an intracranial tumor (excluding meningiomas \\\u003C2 cm in diameter) or mass effect caused by a tumor, such as midline shift;\n3. Cerebral embolism caused by infection or bacterial endocarditis;\n4. The culprit vessel lesion is considered to be chronic atherosclerotic stenosis and occlusion;\n5. Pre-procedure imaging suggests that the lesion is due to dissection;\n6. Previous intracranial aneurysm or vascular malformation in the culprit vessel;\n7. Presence of a life-threatening illness within 6 months that would prevent 3-month follow-up;\n8. Pregnancy, psychiatric illness, severe hepatic or renal insufficiency, severe heart failure;\n9. Concurrent participation in another clinical drug or device study;\n10. Metastatic tumor;\n11. Systemic infection;\n12. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.",{"count":108,"type":21},708,[24],"This is a multicenter, open-label, blinded-endpoint, randomized controlled trial comparing super large bore catheter aspiration versus stent retriever thrombectomy as the first-line technique for anterior circulation large vessel occlusion in acute ischemic stroke. Eligible patients with acute ischemic stroke due to internal carotid artery intracranial segment and\u002For middle cerebral artery M1 occlusion will be randomized 1:1 to receive either aspiration using a super large bore catheter (inner diameter ≥0.080 inch) or stent retriever thrombectomy (allowing balloon guiding catheters or intermediate catheters with inner diameter \\\u003C0.080 inch). The primary outcome is the ordinal modified Rankin Scale score at 90 days post-procedure. Key secondary outcomes include the proportion of patients with mRS 0-2 at 90 days, change in NIHSS at 24 hours and 7 days, and various angiographic and safety endpoints. The trial plans to enroll 708 patients across approximately 30 centers in China. The total study duration is 24-36 months, with each patient participating for 3 months.",[27],[113,114,27],"Endovascular thrombectomy","Super Large Bore Catheter","2026-06-25",{"date":90,"type":40},{"date":118,"type":21},"2026-07-15",{"date":120,"type":21},"2028-03-30",{"name":122,"class":47},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":98},"100643707","rise-stroke-mobility-study-100643707","NCT07638462","RIsE Stroke Mobility Study","RIsEStroke (Recovery Insights Into Early Mobility Post Stroke)","RIsE","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Hospitalized patients with acute ischemic stroke\n* Initial National Institutes of Health Stroke Scale (NIHSS) score of 10 or greater\n* Baseline modified Rankin Scale (mRS) score of 0-2\n* Current modified Rankin Scale (mRS) score of 3-5\n\nExclusion Criteria:\n\n* Current or expected End-of-life discussions\n* Current plans for surgical intervention\n* Patients with pre-mRS of 3-5\n* Patients with orthopedic, musculoskeletal, integumentary injury that would prevent safe weight bearing, mobility or equipment use\n* Uncontrolled cardiorespiratory dysfunction or disease\n* Active\u002Funcontrolled seizures\n* Isolation status that would prevent mobility outside of the room\n* Weight that exceeds the safe limits of mobility equipment",{"count":132,"type":21},50,[24],"This study is designed to better understand how patients with severe stroke move during their hospital stay. It will track their activity using a small wearable device (activPAL) along with standard mobility information already collected in clinical care. The goal is to learn what typical movement patterns look like early after a stroke and how well patients meet mobility goals while in the hospital. What is learned from this study may allow determination of how treatment for stroke patients may be improved to improve patient long-term mobility.",[27],[137,138,139],"stroke","mobility","advanced therapy","2026-06-24",{"date":115,"type":40},{"date":143,"type":21},"2026-07",{"date":72,"type":21},{"name":146,"class":47},"Wake Forest University Health Sciences",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":98},"100644794","effectiveness-of-early-intervention-with-virtual-reality-based-interactive-rehabilitation-on-upper-extremity-muscle-strength-cognitive-status-hospital-anxiety-and-exercise-self-efficacy-in-patients-with-acute-ischemic-stroke-100644794","NCT07674329","Effectiveness of Early Intervention With Virtual Reality-Based Interactive Rehabilitation on Upper Extremity Muscle Strength, Cognitive Status, Hospital Anxiety, and Exercise Self-Efficacy in Patients With Acute Ischemic Stroke","Effectiveness of Early Intervention With Virtual Reality-based Interactive Rehabilitation on Upper Extremity Muscle Strength, Cognitive Status, Hospital Anxiety and Exercise Self-efficacy in Patients With Acute Ischemic Stroke: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of acute ischemic stroke with ICD-10 codes: G45-G46.8, I63-I68.8.\n* Within 10 days (inclusive) of stroke symptom onset.\n* Age 18\\~85 years or older.\n\nExclusion Criteria:\n\n* Comorbid neuromuscular or orthopedic conditions affecting upper limb function.)\n* Recurrence of stroke or onset of seizures during the study period.\n* Severe visual impairment or visuospatial neglect.\n* Inability to cooperate or refusal to participate in the study.","85 Years",{"count":156,"type":21},100,[24],"This interventional study evaluates the impact of early virtual rehabilitation, starting 24 hours post-diagnosis of acute ischemic stroke, on upper limb strength, cognitive status, and self-efficacy. The goal is to establish more effective rehabilitation protocols for acute ischemic stroke patients and to boost their motivation to participate in training.",[27],[161],"Virtual reality, acute ischemic stroke, early rehabilitation, upper limb muscle strength, cognitive status, self-efficacy, anxiety","2026-06-23",{"date":90,"type":40},{"date":165,"type":40},"2025-03-07",{"date":167,"type":21},"2026-10-01",{"name":169,"class":47},"Tri-Service General Hospital (TSGH)",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100635432","sivelestat-sodium-as-an-adjunct-to-endovascular-thrombectomy-for-acute-anterior-circulation-large-vessel-occlusion-100635432","NCT07552610","Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion","Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* 1.Symptoms and signs consistent with focal ischemia in the anterior circulation;\n* 2.Large vessel occlusion of the anterior circulation (internal carotid artery, M1\u002FM2 segment of the middle cerebral artery) confirmed by CTA\u002FMRA\u002FDSA;\n* 3.Undergoing mechanical thrombectomy;\n* 4.Age between 18-80 years, both male and female;\n* 5.Pre-stroke modified Rankin Scale (mRS) score ≤1;\n* 6.Time from symptom onset to thrombectomy ≤24 hours, including wake-up stroke or unwitnessed stroke; symptom onset is defined as the \"last known well\" (LKW);\n* 7.National Institutes of Health Stroke Scale (NIHSS) score ≥6 at admission;\n* 8.ASPECTS ≥3 for anterior circulation occlusion;\n* 9.Written informed consent provided by the patient or their legal representative.\n\nExclusion Criteria:\n\n* 1．Simultaneous acute occlusion of both the anterior and posterior circulation, or bilateral acute large-vessel occlusion in the anterior circulation;\n* 2．Failure to obtain a baseline NIHSS score before sedation or intubation by a neurologist or emergency physician;\n* 3．Seizure at stroke onset that precludes assessment of the baseline NIHSS score;\n* 4．Bilateral dilated pupils;\n* 5．Known allergy to sivelestat sodium or any of its excipients;\n* 6．Severe allergy or absolute contraindication to iodinated contrast agents;\n* 7．Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy;\n* 8．Blood glucose \\\u003C50 mg\u002FdL (2.8 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL);\n* 9．Platelet count \\\u003C50 \\* 10⁹\u002FL;\n* 10．Hereditary or acquired bleeding tendency, coagulation factor deficiency, current oral anticoagulant use with INR \\>1.7, or oral anticoagulant treatment within the previous 48 hours;\n* 11．Severe renal failure, defined as serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL), glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin, or requirement for hemodialysis or peritoneal dialysis;\n* 12．Inability to complete the 90-day follow-up (e.g., no fixed residence or overseas patients);\n* 13．Suspected vasculitis or septic embolism;\n* 14．Suspected aortic dissection;\n* 15．Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, tumor, or arteriovenous malformation;\n* 16．Significant mass effect with midline shift;\n* 17．Evidence of internal carotid artery dissection causing flow limitation;\n* 18．Neurological disease or psychiatric disorder that may interfere with evaluation of the patient's condition;\n* 19．Pregnant or breastfeeding women;\n* 20．Confirmed rheumatic or autoimmune disease with long-term use of immunosuppressants or corticosteroids;\n* 21．Current treatment with chemotherapy or other immunomodulatory agents (e.g., recombinant human granulocyte colony-stimulating factor, Xuebijing, or ulinastatin);\n* 22．Participation in another clinical trial that may interfere with the results of this study;\n* 23．Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation or may pose a significant risk to the patient.",{"count":178,"type":21},868,[24],"Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, \"futile recanalization\" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.\n\nSivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.",[27,64,182,183],"Thrombectomy","Neutrophil Extracellular Trap Formation",[185,186,187],"Endovascular Thrombectomy","Sivelestat Sodium","Neutrophil elastase","2026-06-22",{"date":115,"type":40},{"date":188,"type":40},{"date":192,"type":21},"2029-05-31",{"name":194,"class":47},"Xuanwu Hospital, Beijing",2,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":195},"100632850","phase-4-safety-and-efficacy-of-adjunctive-gm1-to-mechanical-thrombectomy-for-acute-anterior-circulation-large-vessel-occlusion-100632850","NCT07519044","Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion","Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study-IAT-GIANT (Ganglioside GM1 to Improve Outcomes in Anterior CirculatioN Thrombectomy)","IAT-GIANT","Inclusion Criteria:\n\n* 1.Age ≥18 years and ≤80 years\n* 2.Symptoms and signs consistent with anterior circulation ischemia;\n* 3.Computed tomography angiography (CTA) \u002Fmagnetic resonance angiography (MRA) \u002Fdigital subtraction angiography (DSA) confirmed occlusion of intracranial segment of internal carotid artery (ICA) or M1\u002FM2 segments of the middle cerebral artery (MCA M1\u002FM2);\n* 4.Acute ischemic stroke (AIS) selected for emergency endovascular treatment;\n* 5.Premorbid mRS ≤1;\n* 6.Time from symptom onset to randomization was within 24 hours, including patients with wake-up stroke or unwitnessed stroke; The time of symptom onset was defined as the Last Known Well (LKW);\n* 7.National Institutes of Health Stroke Score (NIHSS) ≥6 at admission;\n* 8.ASPECTS ≥3;\n* 9.Informed consent obtained from the patient or his\u002Fher legal representative.\n\nExclusion Criteria:\n\n* 1.Simultaneous acute occlusion of large vessels in both the anterior and posterior circulation or bilateral cerebral hemispheres.\n* 2.Baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation;\n* 3.Seizures at stroke onset which would preclude obtaining a baseline NIHSS;\n* 4.Bilateral dilated pupils;\n* 5.Allergy to GM1 or excipients;\n* 6.Severe contrast allergy or absolute contraindication to iodinated contrast;\n* 7.Systolic pressure \\>185 mmHg or diastolic pressure \\>110 mmHg, and cannot be controlled by antihypertensive drugs;\n* 8.Blood glucose \\\u003C50 mg\u002Fdl (2.8 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL);\n* 9.Platelet \\\u003C50\\*10\\^9\u002FL;\n* 10.Known genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or oral anticoagulant drugs and INR \\> 1.7, or treated with direct oral anticoagulant agents in the prior 48 hours;\n* 11.Known Severe renal Failure as defined by a serum creatinine \\> 3.0 mg\u002Fdl (or 265.2 μmol\u002Fl) or glomerular filtration rate (GFR) \\\u003C30, or patient requires hemodialysis or peritoneal dialysis;\n* 12.Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.);\n* 13.Presumed vasculitis or septic embolization;\n* 14.Suspicion of aortic dissection;\n* 15.Evidence indicates intracranial tumors (excluding small meningiomas), acute intracranial hemorrhage, tumors, or arteriovenous malformations (AVMs).\n* 16\\. Significant mass effect causing midline shift.\n* 17\\. The patient has neurological disease or mental disorder before onset, which affects the assessment of the condition;\n* 18.Females who are pregnant or in lactation;\n* 19.Hereditary glycolipid metabolic disorders (ganglioside storage diseases, such as familial amaurotic idiocy, retinal degenerative diseases);\n* 20.Autoimmune diseases, spine injuries, demyelinating diseases (e.g., Guillain-Barre syndrome)\n* 21.Participating in other clinical trials that could confound the evaluation of the study;\n* 22.Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.",{"count":178,"type":21},[206],"PHASE4","Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to \"futile recanalization\" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.",[63,27],[210,65,211],"GM1","Acute Anterior Circulation Large Vessel Occlusion",{"date":140,"type":40},{"date":214,"type":40},"2026-05-14",{"date":216,"type":21},"2028-08-31",{"name":194,"class":47},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":98},"100644479","phase-3-direct-angio-suite-acute-stroke-intervention-with-ctdsa-hybrid-emergency-stroke-unit-100644479","NCT07670065","Direct Angio Suite Acute Stroke Intervention With CT\u002FDSA Hybrid Emergency Stroke Unit","Direct Angio Suite Acute Stroke Intervention With CT\u002FDSA Hybrid Emergency Stroke Unit to Reduce Time to Endovascular Reperfusion for Acute Ischemic Stroke","Inclusion Criteria\n\n1. Age 18-60 years;\n2. Clinical diagnosis of acute ischemic stroke eligible for immediate endovascular treatment;\n3. Time from symptom onset or last known well ≤ 24 hours;\n4. Intravenous intracranial and cervical CT angiography completed;\n5. Confirmed target vessel occlusion amenable to endovascular intervention based on intravenous intracranial and cervical CT angiography findings;\n6. Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria\n\n1. Known contrast agent allergy;\n2. Renal insufficiency with GFR (glomerular filtration rate) \\\u003C 45 mL\u002Fmin\u002F1.73 m²;\n3. History of kidney transplantation;\n4. Concomitant diabetes mellitus with current use of metformin;\n5. Women who are pregnant, breastfeeding, or have a positive pregnancy test at admission;\n6. Refractory hypertension (defined as systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) (Note: patients may be enrolled if blood pressure is successfully reduced and maintained at an acceptable level with antihypertensive therapy);\n7. Intracranial space-occupying lesion or other conditions deemed unsuitable for endovascular intervention on imaging;\n8. Any other serious comorbidity or complication that may interfere with study conduct or evaluation.","60 Years",{"count":227,"type":21},232,[229],"PHASE3","This study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic stroke who are eligible for endovascular thrombectomy within 24 hours of symptom onset will be enrolled. Participants will be randomly assigned to one of two groups. In the intervention group, participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images. In the control group, participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT. The primary endpoint is puncture-to-successful-reperfusion time (PRT); if successful reperfusion is not achieved, the end-of-procedure time will be used.",[27,64],[233,234,65,235],"Sliding CT\u002FDSA","One-stop Management","Emergency Stroke Care","2026-06-21",{"date":238,"type":40},"2026-06-26",{"date":240,"type":21},"2026-06-08",{"date":242,"type":21},"2027-10-15",{"name":244,"class":47},"Beijing Tiantan Hospital",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100492369","phase-3-assess-the-safety-and-efficacy-of-sovateltide-in-patients-with-acute-cerebral-ischemic-stroke-100492369","NCT05691244","Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke","A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.","RESPECT-ETB","Inclusion Criteria:\n\nA patient will be eligible for inclusion in the study if he\u002Fshe fulfills the following criteria:\n\n1. Adult males or females aged 18 - 80 years of age.\n2. Consent obtained per national laws and regulations, and in accordance with the applicable ethics committee requirements prior to study procedures.\n3. A stroke is ischemic in origin that is diagnosed clinically and\u002For radiologically confirmed by Computed Tomography (CT) scan or diagnostic magnetic resonance imaging (MRI) prior to enrolment. No hemorrhage as proved by cerebral CT\u002FMRI scan.\n4. Cerebral ischemic stroke patients presenting within 24 hours after the onset of symptoms with NIHSS score of ≥8 and \\\u003C20, NIHSS Level of Consciousness (1A) score \\\u003C2 at the time of screening. This includes cerebral ischemic stroke patients who completely recovered from earlier episodes before having a new or fresh stroke having a pre-stroke historical measure of mRS score of 0-2.\n5. The patient is \\\u003C24 hours from the time of stroke onset when the first dose of sovateltide is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when the patient was last seen or was self- reported to be normal.\n6. Reasonable expectation of availability to receive the full sovateltide\u002Fplacebo course of therapy and to be available for subsequent follow-up visits.\n\nExclusion Criteria:\n\nA patient will not be eligible for inclusion in this study if they meet any of the following exclusion criteria:\n\n1. Patients receiving endovascular therapy or is a candidate for any surgical intervention for the treatment of stroke, which may include but not limited to endovascular techniques.\n2. Patients classified as comatose are defined as a patient who requires repeated stimulation to attend or is obtunded and requires strong or painful stimulation to make movements (NIHSS Level of Consciousness (1A) score ≥2).\n3. Evidence of intracranial hemorrhage (intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan.\n4. Known pregnancy and lactating women.\n5. Known medical history of neurological (other than current acute ischemic stroke) or psychiatric condition that, in the investigator's opinion, would confound the neurological and functional evaluations, lead to further deterioration of neurological status, or interfere with participation in this study.\n6. Concurrent participation in any other therapeutic clinical trial.\n7. Evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol impair the assessment of outcome, or in which sovateltide therapy would be contraindicated or might cause harm to the patient.",{"count":254,"type":21},514,[229],"Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.",[27,258],"Cerebral Stroke",[260],"Endothelin B Receptors","2026-06-19",{"date":140,"type":40},{"date":264,"type":40},"2025-07-24",{"date":266,"type":21},"2026-11",{"name":268,"class":75},"Pharmazz, Inc.",54,{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":98},"100641225","oropharyngeal-flushing-suction-tube-with-laryngoscope-for-stroke-associated-pneumonia-100641225","NCT07647666","Oropharyngeal Flushing Suction Tube With Laryngoscope for Stroke-Associated Pneumonia","Translational Application of an Oropharyngeal Flushing Suction Tube Combined With Laryngoscope for Improving Prognosis in Stroke-Associated Pneumonia: A Prospective Randomized Controlled Trial","OFST-SAP","Inclusion Criteria:\n\n1. Confirmed acute ischemic stroke by cranial CT or MRI.\n2. Age 18 years or older.\n3. Glasgow Coma Scale score of 6 to 12.\n4. No artificial airway and no requirement for invasive mechanical ventilation at enrollment.\n5. Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Existing artificial airway or invasive mechanical ventilation at ICU admission or screening.\n2. Pre-existing pulmonary infection at enrollment, or definite extra-pulmonary organ or tissue infection during the study period.\n3. Hemorrhagic blood disorder, clinically significant coagulopathy, or bleeding risk precluding laryngoscopy.\n4. Oral or maxillofacial deformity impeding laryngoscope insertion.\n5. Cervical spine fracture, atlantoaxial instability, or other condition restricting neck extension or movement.\n6. Confirmed or suspected pregnancy.\n7. Irreversible critical illness with anticipated survival less than 28 days.\n8. Uncontrolled hypertension or recurrent malignant arrhythmias.\n9. Other conditions judged by investigators to make participation unsuitable.",{"count":279,"type":21},120,[24],"Stroke-associated pneumonia is a common and clinically important complication after acute ischemic stroke, especially in non-intubated patients with impaired consciousness and reduced cough or swallowing reflexes. Conventional oral or nasal suction may be insufficient for removing deep oropharyngeal secretions. This prospective randomized controlled trial will evaluate whether a patented oropharyngeal flushing suction tube combined with direct laryngoscopy reduces the 28-day incidence of stroke-associated pneumonia compared with laryngoscope-guided standard suction and conventional oral\u002Fnasal suction.",[27,283],"Stroke-Associated Pneumonia (SAP)",[285,286,287,288,289],"Oropharyngeal Suction","Laryngoscope","Airway Management","Suction Tube","Aspiration Pneumonia","2026-06-17",{"date":292,"type":40},"2026-06-18",{"date":42,"type":21},{"date":295,"type":21},"2029-07-31",{"name":297,"class":47},"Shanghai Pudong New Area Gongli Hospital",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":307,"studyType":308,"phases":4,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":98},"100641607","real-world-clinical-evaulation-of-medtronic-neurovascular-products-for-acute-ischemic-stroke-recanova-registry-100641607","NCT07599904","REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)","RECANOVA","Inclusion Criteria:\n\n1. Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements.\n2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\\* during treatment for acute ischemic stroke.\n3. Participant is 18 years of age or older.\n\nExclusion Criteria:\n\n1. Participant who may be unable to complete follow-up within the registry.\n2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.\n3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug\u002Fdevice study that may confound the study results based on Principal Investigator's discretion.",{"count":306,"type":21},1500,"90 Days","OBSERVATIONAL","Post-Market Registry",[27],"2026-06-16",{"date":292,"type":40},{"date":314,"type":21},"2026-06",{"date":316,"type":21},"2031-07",{"name":318,"class":75},"Medtronic Neurovascular Clinical Affairs",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":98},"100642621","phase-3-rhtnk-tpa-for-acute-ischemic-stroke-under-simplified-imaging-in-the-extended-time-window-100642621","NCT07606807","rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window","rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window: A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Trial","SIMPLIFIED","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Presumed acute ischemic stroke of the anterior circulation.\n3. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrollment; including wake-up stroke and unwitnessed stroke, onset time refers to 'last-known well time'.\n4. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive).\n5. Limited early ischemic changes on non-contrast CT (NCCT).\n6. Written informed consent signed by patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n1. Clearly demarcated hypodensity on non-contrast CT related to the current stroke, with limited anticipated clinical benefit as judged by the investigator.\n2. Intracranial or subarachnoid hemorrhage identified on baseline NCCT.\n3. Endovascular thrombectomy (EVT) planned at the time of randomization.\n4. Pre-stroke mRS≥2.\n5. Allergy to the test drug and its ingredients.\n6. Severe head trauma or ischemic stroke in the last 3 months.\n7. Intracranial or intraspinal surgery within 3 months before enrollment.\n8. Intracranial tumor or large-size aneurysm found before enrollment.\n9. Gastrointestinal or urinary system hemorrhage within the past 3 weeks.\n10. Active visceral bleeding.\n11. Aortic arch dissection confirmed by examination or medical history.\n12. Infective endocarditis confirmed by examination or medical history.\n13. Platelet count less than 100 × 109 \u002FL.\n14. Patients received heparin or low-molecular-weighted heparin treatment within 24h before enrollment.\n15. Pregnant or lactating women.\n16. Blood glucose \\\u003C50 mg\u002Fdl (2.78mmol\u002FL) or \\>400 mg\u002Fdl (22.2mmol\u002FL) during screening.\n17. Uncontrolled hypertension with persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg, refractory to medical management.\n18. Life expectancy less than 6 months due to malignancy, severe cardiopulmonary disease, or other terminal illness.\n19. Participating in other trials.\n20. Other conditions deemed unsuitable for the study by the investigator, such as inability to comprehend or comply with study procedures or follow-up due to mental illness, cognitive or emotional disorder.",{"count":328,"type":21},750,[229],"The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic stroke (AIS) presenting in the extended 4.5-24 hour window, using a simplified imaging selection strategy based solely on non-contrast CT (NCCT).",[27],[333,334,335,336,337],"Intravenous Thrombolysis","Extended Time Window","Simplified Imaging","Non-contrast CT","Tenecteplase","2026-06-11",{"date":340,"type":40},"2026-06-15",{"date":42,"type":21},{"date":343,"type":21},"2028-12-01",{"name":345,"class":47},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":98},"100464379","large-artery-occlusion-treated-in-extended-time-with-mechanical-thrombectomy-trial-100464379","NCT05326932","Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial","An Investigator Initiated and Conducted, Prospective, Multicenter, Randomized Outcome-blinded Study of Treating Mechanical Thrombectomy Exceeding 24 Hours in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion","LATE-MT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Present 24-72 hours of stroke onset or last seen well\n3. Clinical diagnosis of AIS due to anterior circulation LVO (from internal carotid artery (ICA) extracranial segment to middle cerebral artery (MCA) M1 and M2 segment) on brain imaging\n4. National Institute of Health stroke scale (NIHSS) ≥6 at randomisation\n5. Viable cerebral tissue on computerized tomography perfusion (CTP) assessed: infarct core volume \\\u003C50 mL, mismatch ratio ≥1.8, and mismatch volume ≥15 mL\n6. Written informed consent (by patient or proxy, according to local requirements)\n\nExclusion Criteria:\n\nClinical Exclusion Criteria\n\n1. Considered unlikely to benefit from trial (e.g. advanced dementia, major pre-stroke disability (prior modified Rankins scale (mRS) ≥2), high likelihood of early death), as judged by the responsible treating clinician\n2. Major co-morbid disease that could interfere with outcome assessments and follow-up (e.g. cancer, severe heart failure, kidney failure)\n3. Pregnancy\n4. Unable to undergo a CTP\n5. Known allergy to iodine, heparin, anaesthesia, or other definite contraindication to receiving endovascular treatment (EVT) procedure\n6. Seizures at stroke onset or before randomization and baseline NIHSS scores cannot be accurately determined\n7. Baseline blood glucose of \\\u003C50 mg\u002FdL (2.78 mmol\u002FL) or \\>400 mg\u002FdL (22.20 mmol\u002FL)\n8. Baseline platelet count \\\u003C 50,000\u002FuL\n9. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with International normalized ratio (INR) \\>3\n10. Severe, sustained hypertension that can not be controlled by medication (systolic BP \\>220 mmHg or diastolic BP \\>120 mmHg)\n11. Presumed septic embolus, suspicion of bacterial endocarditis\n12. EVT attempted after stroke onset\n13. Unlikely to participate in follow-up assessments\n14. Currently participating in another trial that may affect outcomes.\n15. Any other condition that, in the opinion of the investigator will pose a significant hazard to the subject if participating in the trial.\n\nNeuroimaging Exclusion Criteria\n\n1. Intracranial hemorrhage (ICH), including parenchymal hemorrhage, ventricular hemorrhage, subarachnoid hemorrhage, and subdural\u002Fexsanguination\n2. Evidence of intracranial malignant tumor\n3. Significant mass effect with midline shift\n4. Aortic dissection\n5. Intracranial stent implanted in the same vascular territory\n6. Any other condition that may affect EVT procedure, like the tortuous vascular path the device is difficult to reach the target position or difficult to recover\n7. Occlusions in multiple vascular territories confirmed on Computerized tomography angiography (CTA)\u002F Magnetic resonance imaging angiography (MRA) (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion)",{"count":355,"type":21},336,[24],"A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS",[27],[360,361,33,362,363],"Acute ischemic stroke","Large vessel occlusion","Extended time","Randomised clinical trial","2026-06-09",{"date":338,"type":40},{"date":367,"type":40},"2022-11-03",{"date":369,"type":21},"2028-03-31",{"name":371,"class":47},"Fudan University",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":392},"100620721","phase-3-a-study-to-test-if-tenecteplase-helps-people-to-recover-from-an-acute-stroke-when-given-more-than-45-hours-after-the-person-was-last-seen-well-100620721","NCT07361302","A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well","TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue","TENACITY","Inclusion criteria:\n\n1. Male or female ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years\n2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n3. Acute ischaemic stroke (including wake-up stroke) affecting the supratentorial circulation (anterior cerebral artery (ACA), middle cerebral artery (MCA), and posterior cerebral arteries (PCA)) last known well \\>4.5 h before time of presumed randomisation\n4. Pre-stroke modified Rankin scale (mRS) ≤1\n5. Imaging eligibility by magnetic resonance imaging (MRI)computed tomography (CT)\n\nExclusion criteria:\n\n1. Intention to proceed to mechanical thrombectomy (MT) at the same site (hospital) of randomisation\n2. Occlusion of the internal carotid artery (ICA)\n3. High-risk patients (increased risk of thrombolysis related hemorrhage)\n4. Any intracranial hemorrhage detected on non-contrast computed tomography (NCCT) or MRI scans\n5. Contra-indication to contrast brain imaging with CT and MRI\n6. Severe stroke as assessed clinically (National Institute of Health Stroke Scale (NIHSS) \\> 25)\n7. Non-disabling minor stroke symptoms (NIHSS ≤5), or rapidly improving symptoms at the discretion of the investigator\n8. Imaging or clinical findings not indicative of acute ischemic stroke or suggesting stroke older than 72 h\n9. Patients scheduled to receive intravenous (i.v.) thrombolysis as standard of care Further exclusion criteria apply.",{"count":381,"type":21},1325,[229],"This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot.\n\nThe purpose of this study is to find out whether a medicine called tenecteplase helps people recover from an acute stroke. Tenecteplase is already used to treat people within 4.5 hours after they had a stroke. This study tests if tenecteplase also helps if it is given more than 4.5 hours after the stroke.\n\nParticipants are put into 2 groups randomly, which means by chance. One group gets tenecteplase as a single injection into a vein. The other group receives standard medical practice. Participants have an equal chance of receiving tenecteplase or the standard treatment.\n\nParticipants are in the study for about 3 months. In the beginning, participants stay in the hospital for about 1 week. During the study, participants have 7 clinical examinations or visits. The last 2 of these visits will likely be done from home, allowing participants to complete certain assessments remotely. Doctors regularly test participants' recovery using a scale that measures the level of disability or dependence in daily activities. The results are compared between the 2 groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.",[27],{"date":364,"type":40},{"date":387,"type":40},"2026-02-17",{"date":389,"type":21},"2027-10-02",{"name":391,"class":75},"Boehringer Ingelheim",242,{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":98},"100600228","efficacy-and-safety-of-tenecteplase-intravenous-thrombolysis-in-acute-posterior-circulation-ischemic-stroke-within-45-24-hours-after-onset-100600228","NCT07094763","Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset","Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Meeting at least one of the following criteria: acute posterior circulation ischemic stroke confirmed by MRI; symptomatic stenosis or occlusion of a posterior circulation large vessel on vascular imaging (CTA\u002FMRA\u002FDSA); perfusion imaging demonstrating clinically relevant hypoperfusion in the posterior circulation territory.\n3. Onset time between 4.5-24 hours (for wake-up stroke or unwitnessed stroke, onset time is defined as the midpoint between last known well and symptom detection).\n4. NIHSS score\\>3.\n5. PC-ASPECTS ≥7 (if discrepancy exists between DWI and CT findings, CT assessment takes precedence).\n6. Pre-stroke mRS ≤1.\n7. Signed informed consent by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindication to tenecteplase or its components.\n2. Planing to receive endovascular therapy with thrombectomy, angioplasty or stenting whin 3 months.\n3. Acute anterior circulation infarction confirmed by MRI, anterior circulation large vessel occlusion on vascular imaging (CTA\u002FMRA\u002FDSA), or anterior circulation hypoperfusion on perfusion imaging.\n4. History of intracranial hemorrhage.\n5. Stroke, myocardial infarction, severe traumatic brain injury, or intracranial\u002Fspinal surgery within the preceding 3 months.\n6. Intracranial tumor, arteriovenous malformation (AVM), or giant aneurysm.\n7. Active internal bleeding, major surgery, trauma, gastrointestinal\u002Furinary tract bleeding within 3 weeks.\n8. Non-compressible arterial puncture within 1 week.\n9. Suspected aortic dissection.\n10. Clinically significant bleeding or coagulopathy, including: Warfarin use with INR \\>1.7 or PT \\>15 s; Low-molecular-weight heparin within 24 hours; Direct oral anticoagulants within 48 hours; Laboratory abnormalities (e.g., APTT \\>40 s).\n11. Platelet dysfunction or platelet count \\\u003C100×10⁹\u002FL.\n12. Uncontrolled hypertension (systolic BP \\>180 mmHg or diastolic BP \\>110 mmHg unresponsive to antihypertensive therapy).\n13. Uncontrolled hypoglycemia\u002Fhyperglycemia (\\\u003C50 mg\u002FdL \\[2.8 mmol\u002FL\\] or \\>400 mg\u002FdL \\[22.2 mmol\u002FL\\]).\n14. Pregnancy or lactation.\n15. A life expectancy of less than three months.\n16. Participation in other clinical trials within 3 months or ongoing trial enrollment.\n17. Inability to follow up (e.g., no fixed residence, overseas patients).\n18. Patient deemed unsuitable for the trial by site investigator.","100 Years",{"count":402,"type":21},406,[24],"This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.",[27],[407,360,408,409],"TNK Intravenous Thrombolysis","posterior circulation","Beyond optimal time window","2026-06-05",{"date":240,"type":40},{"date":413,"type":40},"2025-11-05",{"date":95,"type":21},{"name":46,"class":47},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":98},"100643740","phase-1-human-placenta-derived-3d-mesenchymal-stem-cellsguojianqingke-100643740","NCT07635758","Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke)","A Phase I\u002FIIa Clinical Trial on the Safety, Tolerability, and Preliminary Efficacy of Human Placental-Derived 3D Mesenchymal Stem Cell Injection Administered Via the Intravenous Route in Patients With Acute Ischemic Stroke (AIS): A Randomized, Double-Blind, Placebo-Controlled Study","3D MSC - QK01","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years; any gender\n2. Body weight 45-90 kg\n3. Diagnosed with acute ischemic stroke, with onset between 6 and 72 hours (inclusive) prior to enrollment; received thrombolysis or not planned for thrombolysis and no planned thrombectomy\n4. NIHSS score 6-20, with NIHSS item 1a (Level of Consciousness) \\\u003C2\n5. Participant or legally authorized representative able to understand and provide written informed consent\n\nExclusion Criteria:\n\n1. Significant pre-stroke disability (pre-stroke modified Rankin Scale \\[mRS\\] score ≥2)；\n2. History of intracerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after this ischemic stroke (imaging re-evaluation before planned dosing shows new bleeding within the infarct area accompanied by neurological deterioration \\[e.g., NIHSS total score increased ≥4 points from admission\\], judged by the investigator as unsuitable for clinical trial participation); or presence of cerebrovascular malformation, multiple sclerosis, severe traumatic brain injury history, encephalitis, or other conditions causing stroke-like symptoms\n3. Uncontrolled systemic diseases, including but not limited to: hypertension (systolic BP \\>180 mmHg and\u002For diastolic BP ≥120 mmHg), diabetes (diabetic acute complications such as ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, or hypoglycemic coma within 3 months, or difficult-to-control diabetes \\[blood glucose \\>16.8 mmol\u002FL or \\\u003C2.8 mmol\u002FL\\]), renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), hepatic failure (Child-Pugh Class C), severe heart failure (NYHA Class IV), severe chronic respiratory disease\n4. History of seizure (except secondary epilepsy not currently requiring drug treatment)\n5. History of brain tumor or malignancy within the past 5 years, including concurrent second primary malignancy, except: a) radically excised non-melanoma skin cancer; b) radically treated cervical carcinoma in situ; c) radically treated papillary thyroid carcinoma; d) radically treated localized prostate cancer; e) radically treated ductal carcinoma in situ of the breast\n6. History of any of the following:\n\n   1. Active or uncontrolled autoimmune disease (e.g., antiphospholipid antibody syndrome)\n   2. Protein C or protein S deficiency\n   3. Sickle cell anemia\n   4. Deep vein thrombosis\n   5. Pulmonary embolism\n   6. Cerebrovascular malformation (e.g., moyamoya disease)\n7. Any concomitant disease or physical condition (e.g., severe arthritis, amputation, blindness, severe disability from prior stroke) that, in the investigator's judgment, would significantly interfere with accurate assessment of mRS, NIHSS, or BI scores\n8. Major surgery within the past 30 days (e.g., thoracotomy, cardiac surgery, abdominal surgery, intracranial surgery)\n9. Currently severe illness, including:\n\n   1. Severe heart failure (NYHA Class III-IV)\n   2. Severe febrile illness (any fever within 14 days before dosing requiring systemic anti-infective treatment)\n   3. Primary or secondary immunodeficiency disease, or long-term or recent high-dose immunosuppressant or systemic corticosteroid therapy before screening\n   4. Hemorrhagic disorder or bone marrow transplantation\n   5. Any comorbidity that the investigator believes may shorten survival or limit ability to complete the study\n   6. Uncontrolled depression affecting daily life before stroke, dementia that may affect clinical assessment, or other neurological or psychiatric disorders that the investigator believes may affect study assessment\n10. Uncontrolled active infection; or systemic anti-infective treatment within 7 days before dosing that the investigator assesses may shortly convert to uncontrolled active infection\n11. Organ function meeting any of the following:\n\n    Hematology:\n\n    Absolute neutrophil count (ANC) \\\u003C1.0×10⁹\u002FL Platelets (PLT) \\\u003C75×10⁹\u002FL Hemoglobin (Hb) \\\u003C80 g\u002FL\n\n    Hepatic\u002FRenal Function:\n\n    Alanine aminotransferase (ALT) \\>2.5×ULN Aspartate aminotransferase (AST) \\>2.5×ULN Total bilirubin (TBIL) \\>1.5×ULN Creatinine \\>1.5×ULN\n\n    Coagulation:\n\n    Phase I: Not receiving anticoagulant or antithrombotic therapy: PT and APTT \\>1.25×ULN, INR \\>1.4; Receiving anticoagulant or antithrombotic therapy: PT and APTT \\>1.5×ULN, INR \\>3.0 Phase IIa: Not receiving anticoagulant therapy: APTT \\>2.0×ULN or PT \\>2.0×ULN; Receiving anticoagulant therapy: judged by investigator to have severe bleeding risk\n12. Clinically significant uncorrected electrolyte disturbances (e.g., hyperkalemia, hypernatremia) that the investigator believes may affect study assessment\n13. Unable to undergo head CT\u002FMRI for any reason (e.g., cardiac pacemaker, metal implants, claustrophobia)\n14. History of drug abuse or alcohol abuse within the past year\n15. Allergy to bovine or porcine products, human serum albumin products, or known allergy to gentamicin\n16. Participation in another investigational drug, device study, or stem cell\u002Fimmune cell therapy within 3 months before treatment\n17. History of blood transfusion or vaccination with attenuated\u002Flive vaccine within 3 months before screening\n18. Pregnant or lactating women; or participants with pregnancy plans during the study period, or unwilling to use effective contraception; or females of childbearing potential with positive pregnancy test; or female participants on long-term oral contraceptives (continuous use \\>30 days)\n19. Other reasons deemed by the investigator as unsuitable for participation or inability to complete study procedures (e.g., lack of willingness)",{"count":425,"type":21},24,[427,87],"PHASE1","This is a Phase I\u002FIIa clinical trial evaluating human placental-derived 3D mesenchymal stem cell (MSC) injection in patients with acute ischemic stroke (AIS). Phase I is a single-dose escalation study to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Phase IIa explores preliminary efficacy. Each participant undergoes screening (up to 72 hours before treatment), a single-day treatment period, and follow-up for up to 720 days (24 months).",[27],[431,432],"Acute Ischemic Stroke，AIS","mesenchymal stem cells","2026-06-03",{"date":364,"type":40},{"date":436,"type":40},"2026-06-01",{"date":438,"type":21},"2028-12",{"name":440,"class":47},"Chinese PLA General Hospital",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":4},"100641125","rapid-local-ischemic-postconditioning-on-stroke-after-thrombectomy-100641125","NCT07598799","Rapid Local Ischemic Postconditioning on Stroke After Thrombectomy","Rapid Local Ischemic Postconditioning Following Successful Recanalization After Endovascular Thrombectomy in Large Ischemic Core Stroke","RAPIDIMPROVE","Inclusion Criteria:\n\n1. Age 18-85 years\n2. Diagnosis of acute ischemic stroke\n3. Pre-stroke mRS 0-1\n4. Baseline NIHSS score ≥ 6\n5. Time from symptom onset to start of endovascular procedure (puncture) \\\u003C 24 hours; onset time defined as \"last known well\" time\n6. Imaging criteria: ASPECTS 3-5 on CT, or ASPECTS \\> 5 with acute ischemic core volume (defined as rCBF \\\u003C 30% or ADC \\\u003C 620) ≥ 50 mL\n7. Occlusion of the intracranial segment of the internal carotid artery or the middle cerebral artery (M1\u002FM2), confirmed as the symptomatic culprit vessel\n8. After thrombectomy, the culprit vessel is considered to be occluded by an embolus, and successful recanalization (mTICI 2b\u002F3, i.e., ≥ 50% perfusion) is achieved\n9. Written informed consent signed by the patient or a legal representative\n\nExclusion Criteria:\n\n1. Presence of stenosis (≥ 50%) in the ipsilateral middle cerebral artery, internal carotid artery, or common carotid artery proximal to the occlusion site\n2. Multiple emboli across different circulations (simultaneous anterior and posterior circulation emboli, or simultaneous left and right anterior circulation emboli)\n3. Evidence on CT of extensive cerebral edema, midline shift, significant mass effect, or signs of brain herniation\n4. Presence of a life-threatening disease with a prognosis \\\u003C 6 months, making 3-month follow-up impossible\n5. Severe psychiatric disorder or heart failure\n6. Concurrent participation in another clinical drug or device study\n7. Any other condition that, in the investigator's judgment, makes the subject unsuitable for this study",{"count":450,"type":21},448,[24],"The main goal of this study is to find out if a new, quick \"brain rescue\" procedure can help people recover better from a severe stroke caused by a large vessel occlusion.\n\nWhen someone has this type of stroke, doctors often perform a procedure called an endovascular thrombectomy (EVT). In EVT, they thread a thin tube through a blood vessel up to the brain to remove the clot and restore blood flow. This is a highly effective treatment.\n\nHowever, for some patients, suddenly restoring blood flow can cause additional, unexpected injury to the brain. This is called \"reperfusion injury.\" This study tests a technique called rapid local ischemic postconditioning (RL-IPostC) that might prevent this extra damage. It's a very simple additional step performed immediately after the clot is successfully removed.\n\nThe doctor would briefly inflate and deflate a tiny balloon inside the proximal brain artery after recanalization, creating very short, controlled \"pauses\" in blood flow. This is believed to give brain cells a gentler \"wake-up\" call, helping them tolerate the return of oxygen-rich blood.\n\nThe study will test two different \"doses\" of this procedure (meaning different numbers of inflation\u002Fdeflation cycles) against the standard care (no additional procedure).\n\nPhase IIb (the first part): Which dose of RL-IPostC (high or low) is more promising for reducing early brain swelling (measured by whether the brain's midline has shifted less than 3 mm on a 24-hour scan)? Phase III (the main part): Using the best dose from Phase IIb, does RL-IPostC improve a patient's functional recovery three months later, specifically enabling them to walk and manage daily activities without help? A total of 288 participants who have had a large-vessel occlusion stroke and successful clot removal will be enrolled. If early results look promising but not quite conclusive, the study can increase the total number of participants up to 448 to get a clearer answer.\n\nIf successful, this study could identify a simple, low-cost add-on procedure to a standard stroke treatment that improves long-term recovery and quality of life for thousands of stroke patients. It's a potential new tool to protect the brain after blood flow is restored. This is a carefully designed study testing a gentle \"on\u002Foff\" blood flow technique right after clot removal, to see if it can reduce brain injury and help people walk and live more independently after a severe stroke.",[27],[455,113,456,457],"Ischemic postconditioning","Neuroprotection","Ischemic reperfusion injury",{"date":459,"type":40},"2026-06-04",{"date":461,"type":21},"2026-07-01",{"date":463,"type":21},"2029-05-30",{"name":122,"class":47},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":483,"leadSponsor":485,"locationsCount":4},"100617240","construction-and-evaluation-of-an-intelligent-decision-system-for-reperfusion-therapy-in-acute-ischemic-stroke-100617240","NCT07316049","Construction and Evaluation of an Intelligent Decision System for Reperfusion Therapy in Acute Ischemic Stroke","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of acute ischemic stroke (AIS).\n* Presentation within 24 hours of symptom onset or last-known-well.\n* Evaluated for reperfusion therapy (intravenous thrombolysis and\u002For endovascular treatment).\n\nExclusion Criteria:\n\n* Absence of key clinical or imaging data necessary for analysis.\n* Patients not undergoing reperfusion assessment or outside the pre-defined workflow.\n* Prior participation in other AI-based decision support trials within the past 12 months.\n* Explicit refusal of data use or withdrawal of consent (if applicable).",{"count":472,"type":21},3000,[24],"This multicenter, cluster-randomized controlled trial will evaluate the effectiveness and safety of the LingBao System, an AI-enabled clinical decision support platform for reperfusion therapy in acute ischemic stroke (AIS). Twenty certified stroke centers will be randomized 1:1 to LingBao-assisted care or standard care. Consecutive patients aged 18 years or older who present within 24 hours of symptom onset or last-known-well and are evaluated for intravenous thrombolysis and\u002For endovascular therapy will be prospectively enrolled.\n\nThe study initially plans to enroll approximately 3,000 patients from about 20 certified stroke centers, with approximately 150 patients per center. Because this is a cluster-randomized trial, a pre-specified blinded sample size re-estimation will be performed after approximately 40% of participants have completed the 90-day mRS assessment. The re-estimation will be based only on pooled, blinded information, including cluster size, cluster-size variability, intracluster correlation, follow-up completeness, missingness of the primary outcome, and the overall distribution of the 90-day mRS. No between-group treatment effect will be examined, and any sample size adjustment will only allow an increase in enrollment.\n\nAt intervention sites, clinicians may use the LingBao System during their routine workflows. The platform integrates routinely available clinical and imaging data, automatically estimates onset-to-treatment windows, screens contraindications, and provides evidence-based, guideline-concordant recommendations for reperfusion therapy; all treatment decisions remain at physician discretion.\n\nThe primary endpoint is the 90-day modified Rankin Scale (mRS) score analyzed by ordinal shift. Secondary endpoints include workflow metrics (door-to-needle time and door-to-puncture time), reperfusion treatment rates, early neurological improvement, symptomatic intracranial hemorrhage, and mortality.\n\nThe findings will provide real-world evidence on the clinical value of AI-assisted decision support for reperfusion therapy in AIS and inform broader implementation of intelligent stroke management systems.",[27],[477,478,479],"Reperfusion Therapy","Artificial Intelligence","Clinical Decision Support System","2026-06-02",{"date":459,"type":40},{"date":340,"type":21},{"date":484,"type":21},"2027-02-28",{"name":486,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":494,"targetDuration":496,"studyType":308,"phases":4,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":501,"leadSponsor":503,"locationsCount":98},"100640936","association-between-circulating-bdnf-levels-and-cardioembolic-strokes-in-patients-treated-for-ischemic-stroke-100640936","NCT07624396","Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke","METAPROFIL 1","Inclusion Criteria:\n\n* Individuals who provided informed consent\n* Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI)\n* Patient admitted to the USINV of the Department of General, Vascular, and Degenerative Neurology at the Dijon Bourgogne University Hospital during the inclusion period\n* Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke\n\nExclusion Criteria:\n\n* A person subject to a legal protective measure (guardianship, conservatorship)\n* A person subject to a judicial safeguard measure\n* A pregnant woman, a woman who has recently given birth, or a breastfeeding woman\n* An adult who is legally incapacitated or unable to give consent,\n* A minor",{"count":495,"type":21},150,"36 Months","Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging.\n\nACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications.\n\nThis study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies",[27],{"date":433,"type":40},{"date":314,"type":21},{"date":502,"type":21},"2031-06",{"name":504,"class":47},"Centre Hospitalier Universitaire Dijon",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":524,"locationsCount":98},"100638388","phase-1-a-phase-i-trial-of-umbilical-cord-mesenchymal-stromal-cells-for-acute-ischemic-stroke-100638388","NCT07628933","A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord-derived Mesenchymal Stromal Cell Injection in Patients With Acute Ischemic Stroke (AIS)","Inclusion Criteria:\n\n* Age ≥18 years, both genders included.\n* Clinical diagnosis of anterior circulation ischemic stroke, and able to receive the investigational product within 48 hours after the onset of stroke symptoms.\n* National Institutes of Health Stroke Scale (NIHSS) score of 6-20 (inclusive), with a score of \\\u003C2 on item Ia of the NIHSS.\n* Pre-stroke modified Rankin Scale (mRS) score ≤1.\n* The participant voluntarily agrees to participate in this study, signs the informed consent form personally or via a legal guardian, and has good compliance.\n\nExclusion Criteria:\n\n* Planned or already performed thrombectomy for the current stroke.\n* Treatment with neuroprotective agents after the current stroke.\n* History of cerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after the current ischemic stroke, and judged by the investigator to be unsuitable for participation in the clinical trial.\n* Uncontrolled systemic diseases, including but not limited to: hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure ≥100 mmHg), diabetes mellitus (acute diabetic complications such as ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis, or hypoglycemic coma within the past 3 months, or glycated hemoglobin \\>8.5%, or poorly controlled blood glucose \\[blood glucose \\>16.8 mmol\u002FL or \\\u003C2.8 mmol\u002FL\\]), renal disease (eGFR \\\u003C30 mL\u002Fmin), liver failure (Child-Pugh Class C), severe heart failure (New York Heart Association \\[NYHA\\] Class IV), severe chronic respiratory disease.\n* Organ function meeting any one or more of the following criteria:\n\n  1. Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL, platelet count (PLT) \\\u003C100×10⁹\u002FL, hemoglobin (Hb) \\\u003C90 g\u002FL;\n  2. Aspartate aminotransferase (AST) \\>2.5× upper limit of normal (ULN) and\u002For alanine aminotransferase (ALT) \\>2.5×ULN, serum total bilirubin (TBIL) \\>1.5×ULN;\n  3. Creatinine (Cr) \\>1.5×ULN;\n  4. For patients not receiving anticoagulant or antithrombotic therapy: international normalized ratio (INR) \\>1.7 or activated partial thromboplastin time (APTT) \\>1.25×ULN; for patients receiving anticoagulant or antithrombotic therapy: INR \\>3.0 or APTT \\>1.5×ULN.\n* Diagnosis of immunodeficiency disease, or long-term use of immunosuppressants or systemic corticosteroids at high doses within a short period before screening.\n* Epilepsy, Alzheimer's disease, Parkinson's disease, severe depression, or other neurological or psychiatric disorders that, in the investigator's opinion, could affect the participant's ability to participate in the trial or interfere with study assessments.\n* Presence of autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.).\n* Inability to undergo cranial CT\u002FMRI examination for any reason (e.g., metallic implants such as cardiac pacemakers, claustrophobia, etc.).\n* Participation in another clinical trial of an investigational drug within 3 months before screening.\n* Pregnancy, breastfeeding, planned pregnancy, or inability to use effective contraceptive measures.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in this study.",{"count":513,"type":21},35,[427],"Study Methods: The trial consists of two phases, both including a placebo control.\n\nPhase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set. This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial. Dose escalation to the next level is permitted only after safety assessment at 28 days post-dose in the previous group.\n\nPhase Ib (multiple-dose): Based on Phase Ia results, two dose groups will be selected. The product is administered on Day 0, Day 7, and Day 14 (3 doses total). The trial remains randomized, double-blind, and placebo-controlled.",[27,517],"AIS",[517,519],"hUC-MSCs",{"date":410,"type":40},{"date":37,"type":21},{"date":523,"type":21},"2029-11-30",{"name":525,"class":75},"BOE Technology Group Co., Ltd.",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":537,"conditions":538,"keywords":539,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":98},"100639828","phase-3-pro-urokinase-for-extended-window-posterior-circulation-stroke-100639828","NCT07617870","Pro-urokinase for Extended-Window Posterior Circulation Stroke","Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study","PROMISE","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);\n3. Imaging criteria:\n\n   1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;\n   2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;\n4. NIHSS score 4-25;\n5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);\n6. Signed informed consent from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Planned endovascular treatment;\n2. Contradictory to MRI examination;\n3. MRI image not qualified for evaluation;\n4. Serious neurological deficits before onset (mRS≥2);\n5. Obvious head injuries or strokes within 3 months;\n6. Subarachnoid or intracranial hemorrhage;\n7. History of intracranial hemorrhage;\n8. Intracranial tumor, arteriovenous malformation or aneurysm;\n9. Intracranial or spinal cord surgery within 3 months;\n10. Active internal hemorrhage;\n11. platelet count of \\\u003C100000\u002Fmm3;\n12. Aortic arch dissection;\n13. Heparin therapy within 24 hours;\n14. Oral warfarin is being taken and INR\\>1.6 or APTT abnormal;\n15. Oral anticoagulation therapy;\n16. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;\n17. Blood glucose \\\u003C 50 mg\u002Fdl (2.7mmol\u002FL);\n18. Pregnancy;\n19. Neurological deficit after epileptic seizures;\n20. Major surgery within 1 month;\n21. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;\n22. Myocardial infarction within 3 months;\n23. Allergy to study drugs;\n24. Unlikely to adhere to the trial protocol or follow-up;\n25. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;\n26. Participation in other interventional clinical trials within the previous 3 months.",{"count":535,"type":21},586,[229],"This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.",[27],[540,541,542,543],"Recombinant human prourokinase (rhPro-UK)","Posterior circulation ischemic stroke","Extended-window thrombolysis","Intravenous thrombolytic therapy","2026-05-26",{"date":436,"type":40},{"date":436,"type":21},{"date":548,"type":21},"2028-06-30",{"name":550,"class":47},"The First Affiliated Hospital of Zhengzhou University",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":98},"100640935","phase-3-efficacy-and-safety-of-tenecteplase-among-acute-ischemic-stroke-patients-with-recent-ingestion-of-direct-oral-anticoagulant-100640935","NCT07621796","Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant","Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant (ESTER-DOAC)","ESTER-DOAC","Inclusion Criteria:\n\n* Adults (18 years or older) with a suspected acute ischemic stroke and clearly disabling deficits\n* Presenting within 4.5 hours of last known well\n* Able to initiate intravenous thrombolysis within 4.5 hours of last known well\n* On recent DOAC therapy (dabigatran, apixaban, rivaroxaban, edoxaban) and known last dose taken within 48 hours from thrombolysis.\n\nExclusion Criteria:\n\n* Current or history of intracerebral hemorrhage\n* Non-disabling deficits\n* Bleeding disorder (e.g. hemophilia) or advanced liver disease or known INR \\> 1.7 within 6 hours\n* Use of therapeutic low molecular weight heparin or therapeutic dose heparin with elevated PTT\n* ASPECTS \\\u003C 6 or clear hypodensity on CT suggestive of completed infarct\n* Advanced kidney disease (eGFR \\\u003C 30 ml\u002Fmin)\n* Known or suspected aortic dissection\n* Known or high suspicion for infective endocarditis\n* Surgery within 2 weeks\n* Intracranial or intraspinal surgery within 3 months\n* Active internal bleeding or gastrointestinal or urinary tract hemorrhage within 3 weeks\n* Intracranial neoplasm, arterio-venous malformation, or cavernous malformation\n* Major head trauma or ischemic stroke within 3 months\n* Known thrombocytopenia (platelets \\\u003C 100,000)\n* Planned endovascular treatment within 30 minutes of study drug administration (i.e., consent, randomization and administration of study drug must occur at least 30 minutes prior to groin puncture; standard care is not to be delayed and patients in whom endovascular therapy will start sooner will not be enrolled)\n* Comorbid condition with life expectancy of less than 3 months\n* Any condition that precludes thrombolytic therapy as determined by site principal investigator\n* Pregnancy",{"count":560,"type":21},660,[229],"The study will randomize patients with acute ischemic stroke and Direct Oral AntiCoagulants (DOAC) ingestion within 48 hours from enrollment (but otherwise eligible for thrombolysis) to administration of intravenous tenecteplase vs. placebo (1:1).\n\nParticipants will be enrolled at NIH StrokeNet sites across the US and followed for 90-days.\n\nThe primary aim is to determine the efficacy of intravenous tenecteplase (TNK) vs placebo among acute ischemic stroke patients and to determine the safety of TNK among acute ischemic stroke patients within 4.5 hours of last known well who used DOAC within 48 hours prior to thrombolysis. Efficacy and safety endpoints will be the focus of this proposed Phase III study.",[27],[565,566,567,568],"acute ischemic stroke","Oral AntiCoagulants","thrombolysis","intravenous tenecteplase administration",{"date":480,"type":40},{"date":571,"type":21},"2027-01-01",{"date":573,"type":21},"2032-01-30",{"name":575,"class":47},"Hackensack Meridian Health",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":22,"phases":585,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":595,"leadSponsor":597,"locationsCount":98},"100639150","efficacy-and-safety-of-bailout-intracranial-angioplasty-or-stenting-after-thrombectomy-for-acute-intracranial-atherosclerotic-large-vessel-occlusion-angel-reboot-2-100639150","NCT07618052","Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion (ANGEL-REBOOT 2)","Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion: A Clinical Trial Combining a Randomized Controlled Trial and a Concurrent Prospective Observational Cohort","Inclusion Criteria:\n\n1. Age≥18 years.\n2. Time interval from symptom onset to puncture ≤24 hours.\n3. National Institute of Health Stroke Scale (NIHSS) Score ≥6 before randomisation.\n4. Pre-stroke modified Rankin Scale (mRS) of 0-2.\n5. Each patient or their legal representative must provide written informed consent before enrolment.\n\nImaging Inclusion Criteria:\n\n1. For patients with anterior circulation stroke, a CT or DWI-based Alberta Stroke Program Early CT Score (ASPECTS) of ≥6 is required.\n2. For patients with posterior circulation stroke, CT or DWI-based posterior circulation ASPECTS (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of \\\u003C3 are required.\n\nAngiographic Inclusion Criteria:\n\n1. Acute ischemic stroke (AIS) resulting from large vessel occlusion (LVO) involving the intracranial internal carotid artery, the M1 segment of the middle cerebral artery, the V4 segment of the vertebral artery, or the basilar artery, with high suspicion of intracranial atherosclerotic stenosis-related large-vessel occlusion (ICAS-LVO).\n2. Part 1 (RCT): Successful recanalization of the occluded artery (eTICI ≥ 2b) with residual stenosis ≥ 70% after 1-2 thrombectomy attempts.\n\n   Part 2 (Prospective observational cohort): Failure to achieve successful recanalization (eTICI 0-2a) after at least two thrombectomy attempts. All other inclusion criteria are identical to those for Part 1.\n3. Occluded artery amenable to angioplasty (balloon dilation and\u002For stenting) by the judgement of the treating neurointerventionalist.\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (ICH, except microbleeds) on baseline brain imaging.\n2. CT or MR imaging evidence of intracranial tumor (except small meningiomas or cerebral aneurysms \\\u003C 3mm in diameter).\n3. Any indication of intracranial vessel perforation during thrombectomy..\n4. Presence of tandem lesion in the extracranial segment of the internal carotid artery or vertebral artery, or intracranial arterial stenosis with distal vessel occlusion..\n5. Stenosis caused by non-atherosclerotic intracranial arteriopathies (e.g., autoimmune vasculitis, vasospasm, cerebral artery dissection).\n6. Evidence of cardioembolism (e.g., atrial fibrillation, prosthetic heart valve, infective endocarditis, mitral stenosis, atrial myxoma, intracardiac thrombus\u002Fvegetation, left ventricular aneurysm, etc.).\n7. Contraindication for antiplatelet treatment.\n8. Excessive vascular tortuosity or anatomical variants that may preclude successful delivery or positioning of interventional devices.\n9. History of contraindication to the use of contrast medium.\n10. Refractory hypertension (defined as systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg) that cannot be controlled by drug treatment.\n11. Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR\\>1.5.\n12. Blood glucose\\\u003C2.8 or\\>22.2 mmol\u002FL; Platelet count\\\u003C100\\*109\u002FL, serum creatinine\\>2.0 g\u002FL (177 μ mol\u002FL), or glomerular filtration rate\\\u003C30 ml\u002F(min\\*1.73 m2).\n13. Concurrent participation in another drug or device trial, or expected participation within the following 3 months.\n14. Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.).\n15. Known pregnancy or lactation, or positive pregnancy test before randomization (or before enrollment).\n16. Known dementia or psychiatric disorder that precludes completion of neurological assessments and follow-up.\n17. Any other condition deemed by the site investigator to make the patient unsuitable for participation.",{"count":584,"type":21},420,[24],"A multicenter, randomized, open-label, blinded-endpoint trial with a concurrent prospective observational cohort to compare bailout intracranial angioplasty or stenting versus standard therapy on functional outcome, stroke recurrence, and mortality in patients with acute intracranial atherosclerotic stenosis-related large vessel occlusion after thrombectomy.",[588,27,589],"Intracranial Atherosclerotic Stenosis-Related Large Vessel Occlusion","Bailout Angioplasty or Stenting",[591,185,589],"Acute Intracranial Atherosclerotic Stenosis-Related Large Vessel Occlusion","2026-05-25",{"date":436,"type":40},{"date":436,"type":21},{"date":596,"type":21},"2028-06-01",{"name":598,"class":47},"Feng Gao",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":22,"phases":608,"briefSummary":609,"conditions":610,"keywords":614,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":622,"locationsCount":98},"100637603","phase-2-minocycline-after-successful-endovascular-thrombectomy-recanalization-in-acute-anterior-circulation-large-vessel-occlusion-attraction-minoa-100637603","NCT07594314","Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)","Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS score of 0-1;\n3. Time from symptom onset to randomization ≤24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last known well time;\n4. Baseline NIHSS score of 6-25;\n5. ASPECTS ≥6 on non-contrast CT or DWI;\n6. Clinical symptoms attributable to acute occlusion at one of the following sites, confirmed by CTA, MRA, or DSA: intracranial internal carotid artery, M1 segment of the middle cerebral artery, or M2 trunk of the MCA;\n7. Successful recanalization defined as mTICI 2b-3 after mechanical thrombectomy, with no evidence of secondary embolization in non-target vessels; or spontaneous improvement to mTICI 2b-3 on diagnostic angiography prior to thrombectomy with no planned intervention;\n8. Ability of the patient or legally authorized representative to provide written informed consent.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage on CT or MRI;\n2. Bilateral acute stroke or multiple intracranial large vessel occlusions;\n3. Isolated extracranial internal carotid artery occlusion;\n4. History of pseudomembranous colitis or antibiotic-associated colitis;\n5. Known allergy to tetracycline antibiotics, any component of the investigational drug, radiocontrast agents, or nitinol materials;\n6. Known resistance to tetracycline antibiotics;\n7. Use of tetracycline antibiotics within 7 days prior to randomization;\n8. History of intracranial hemorrhage within the past 3 months, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;\n9. Intracranial tumors, vascular malformations, or other space-occupying intracranial lesions;\n10. History of intracranial or spinal surgery within the past 3 months;\n11. History of major surgery or significant trauma within the past 1 month;\n12. Receipt of any of the following treatments within the past 3 months: systemic retinoic acid or androgen\u002Fantiandrogen therapy (e.g., anabolic steroids, spironolactone);\n13. Platelet count \\\u003C100 × 10⁹\u002FL;\n14. Severe hepatic insufficiency, chronic hemodialysis, or severe renal insufficiency (defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>265.2 μmol\u002FL \\[3.0 mg\u002FdL\\]);\n15. Women who are pregnant or lactating, or who have a positive pregnancy test prior to randomization;\n16. Life expectancy \\\u003C6 months (e.g., due to malignancy or severe cardiopulmonary disease);\n17. Participation in another interventional clinical trial that may affect outcome assessment;\n18. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation or poses significant risk (e.g., inability to understand or comply with study procedures or follow-up due to psychiatric, cognitive, or emotional disorders).",{"count":607,"type":21},860,[87,229],"Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective effects, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Prior preclinical and clinical studies suggest that minocycline may improve neurological outcomes in acute ischemic stroke.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute anterior circulation LVO who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces futile recanalization.",[27,611,185,612,613],"Vessel Occlusion","Anterior Circulation Brain Infarction","Minocycline",[27,185,613,615],"Anterior Circulation Large Vessel Occlusion","2026-05-22",{"date":618,"type":40},"2026-05-27",{"date":620,"type":40},"2026-05-21",{"date":438,"type":21},{"name":623,"class":47},"Xiang Luo"]